Trexquant Investment’s Cytek Biosciences CTKB Stock Holding History

Trexquant Investment’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-45,131	Closed	-$153K	–	1650
2025 Q2	$153K	Sell	45,131 -503,873	-92%	-$1.68M	﹤0.01%	1462
2025 Q1	$2.2M	Buy	549,004 +306,405	+126%	+$1.59M	0.03%	833
2024 Q4	$1.57M	Buy	242,599 +80,909	+50%	+$482K	0.02%	953
2024 Q3	$896K	Buy	161,690 +23,296	+17%	+$132K	0.01%	1084
2024 Q2	$772K	Buy	+138,394	New	+$831K	0.01%	1090
2023 Q1	–	Sell	-72,179	Closed	-$737K	–	1489
2022 Q4	$737K	Buy	+72,179	New	+$970K	0.02%	766
2022 Q3	–	Sell	-74,678	Closed	-$801K	–	1439
2022 Q2	$801K	Buy	74,678 +19,082	+34%	+$190K	0.04%	614
2022 Q1	$599K	Buy	+55,596	New	+$751K	0.03%	684

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's CTKB Position: Q3 2025 in Review

Trexquant Investment sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 45,131 shares — an estimated $153K sold.

Trexquant Investment first reported a position in CTKB in Q1 2022 and held it in 8 quarters. The position peaked at $2.2M in Q1 2025. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

Trexquant Investment reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
Trexquant Investment sold 45,131 Cytek Biosciences shares in Q3 2025, an estimated $153K.
Trexquant Investment first reported a position in Cytek Biosciences in Q1 2022 and held it in 8 quarters.
Trexquant Investment's Cytek Biosciences position peaked at $2.2M in Q1 2025.
153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.